Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Illimis Therapeutics

Request full access

Fusion protein platform for neurodegenerative and immune diseases

Seoul, South KoreaFounded 2021Biotech & Life Sciences

About Illimis Therapeutics

Illimis Therapeutics is a South Korean biotechnology company founded in 2021 by President & CEO Sanghoon Park and scientific co-founders Wonsuk Chung and Chanhyuk Kim. The Seoul-based company specializes in developing therapies for central nervous system (CNS) and immune-related diseases.

The firm's business model is centered on its proprietary GAIA (Gas6-mediated Anti-Inflammatory Adaptor) platform. This technology is designed to leverage the therapeutic potential of TAM (Tyro3, Axl, Mer) receptor biology, a key pathway in regulating inflammation and immune responses. The GAIA platform is a bispecific fusion protein that aims to clear misfolded proteins, such as amyloid-β, by using the TAM receptor, thereby inducing phagocytosis (the ingestion of bacteria or other material) without causing harmful neuroinflammation, a common side effect of existing antibody drugs. The company's lead drug candidate, ILM01, is being developed for Alzheimer's Disease and is expected to enter preclinical trials in the second half of 2025. Illimis is also developing therapeutics for other neurodegenerative diseases, including ILM02 for tauopathies and ILM03 for synucleinopathies.

Illimis Therapeutics generates revenue through research grants, strategic partnerships, and venture capital funding. The company has secured significant funding, including a $42 million Series B round in July 2025, bringing its total funding to over $60 million. This round included participation from investors like DSC Investment, Woori Venture Partners, Korea Development Bank, and LB Investment. The firm actively pursues collaborations with global pharmaceutical companies and was selected for the '2025 Global Joint Research to Defeat Dementia' program, securing government research funding. In October 2024, Illimis entered into a research collaboration with Eli Lilly and Company to advance its platform for neurodegenerative disease applications. The company is guided by a Scientific Advisory Board that includes Dr. Greg Lemke of the Salk Institute and Dr. Morgan Sheng of the Broad Institute.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
22.7/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Jul 2025 $49M $195M Maple Investmet Partners · QUAD Ventures · A Ventures · DSC Investment ↗
SERIES AOther financing Apr 2023 $17M $67M Aju IB Investment · Company K Partners · LSK Investment · GS Ventures ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Illimis Therapeutics website traffic

Latest recorded traffic for Illimis Therapeutics is 7.1K monthly website visits, up 914.3% over the last three months.

Latest monthly visits7.1K 3-month web change+914.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Illimis Therapeutics in the Seoul ecosystem

Live from Dealroom

The Illimis Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

22 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A22 investors entered at this stage

  • Aju IB Investment
  • Company K Partners
  • LSK Investment
  • GS Ventures
  • Quad Asset Management
  • WONIK Investment Partners
  • Industrial Bank of Korea
  • NH Investment & Securities
  • STIC Ventures
  • Daily Partners
  • Woori Venture Partners
  • DSC Investment
  • Maple Investmet Partners
  • QUAD Ventures
  • A Ventures
  • LB Investment
  • Korea Development Bank
  • Hana Ventures
  • Schmidt
  • TS investment
  • Shinhan Venture Investment
  • S&S Investment
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇰🇷 South Korea · Seoul HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Illimis Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Illimis Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.